• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea.

作者信息

Kim Seok Jin

机构信息

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Blood Res. 2015 Dec;50(4):187-8. doi: 10.5045/br.2015.50.4.187. Epub 2015 Dec 21.

DOI:10.5045/br.2015.50.4.187
PMID:26770943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4705041/
Abstract
摘要

相似文献

1
Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea.淋巴瘤生存改善联盟（CISL）：韩国淋巴瘤研究的多中心合作模式。
Blood Res. 2015 Dec;50(4):187-8. doi: 10.5045/br.2015.50.4.187. Epub 2015 Dec 21.
2
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.韩国血液学会淋巴瘤工作组淋巴瘤生存改善联盟开展的临床研究综述。
Blood Res. 2013 Sep;48(3):171-7. doi: 10.5045/br.2013.48.3.171. Epub 2013 Sep 25.
3
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.韩国淋巴瘤流行病学及真实临床领域，包括淋巴瘤生存改善联盟（CISL）试验。
Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.
4
Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies.基于淋巴瘤生存改善联盟（CISL）及韩国临床研究的韩国边缘区淋巴瘤的器官特异性考量
Blood Res. 2019 Mar;54(1):4-6. doi: 10.5045/br.2019.54.1.4. Epub 2019 Mar 21.
5
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.韩国的眼内淋巴瘤：淋巴瘤生存改善联盟（CISL）研究
Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.
6
Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL).韩国霍奇金淋巴瘤的临床特征和结局：改善淋巴瘤生存联盟 (CISL)。
Ann Hematol. 2012 Feb;91(2):223-33. doi: 10.1007/s00277-011-1297-x. Epub 2011 Jul 26.
7
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.淋巴瘤生存改善联盟（CISL）：近期成果与未来展望
Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017.52.1.3. Epub 2017 Mar 27.
8
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.利妥昔单抗联合 CVP 方案化疗治疗晚期边缘区淋巴瘤的 II 期临床试验：改善淋巴瘤生存联盟（CISL）研究。
Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.
9
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.R-CVP 方案Ⅱ期研究后行利妥昔单抗维持治疗晚期边缘区淋巴瘤患者：改善淋巴瘤生存（CISL）研究联盟。
Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.
10
Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.非霍奇金淋巴瘤患者卵巢受累的临床特征及其与预后的相关性：改善淋巴瘤生存合作组（CISL）报告。
Leuk Res. 2010 Sep;34(9):1175-9. doi: 10.1016/j.leukres.2010.02.010. Epub 2010 Mar 5.

引用本文的文献

1
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.血清乳酸脱氢酶高度升高与弥漫性大B细胞淋巴瘤患者的中枢神经系统复发相关：一项多中心前瞻性队列研究的结果
Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.

本文引用的文献

1
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.韩国的眼内淋巴瘤：淋巴瘤生存改善联盟（CISL）研究
Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.
2
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松化疗治疗原发性鼻窦弥漫性大B细胞淋巴瘤患者的临床结局及预后：淋巴瘤生存改善联盟的一项研究
Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20.
3
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.韩国血液学会淋巴瘤工作组淋巴瘤生存改善联盟开展的临床研究综述。
Blood Res. 2013 Sep;48(3):171-7. doi: 10.5045/br.2013.48.3.171. Epub 2013 Sep 25.
4
Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).瓦尔达耶尔环边缘区 B 细胞淋巴瘤：临床和预后特征是结内还是结外？改善淋巴瘤生存联盟（CISL）的研究。
Int J Hematol. 2012 Nov;96(5):631-7. doi: 10.1007/s12185-012-1200-0. Epub 2012 Oct 12.
5
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).利妥昔单抗联合 CHOP 化疗治疗肾上腺原发性弥漫性大 B 细胞淋巴瘤的预后因素：来自改善淋巴瘤生存联合组织（CISL）的研究。
J Hematol Oncol. 2012 Aug 13;5:49. doi: 10.1186/1756-8722-5-49.
6
Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008.韩国血液系统恶性肿瘤统计：1999年至2008年的发病率、患病率和生存率
Korean J Hematol. 2012 Mar;47(1):28-38. doi: 10.5045/kjh.2012.47.1.28. Epub 2012 Mar 28.
7
Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study.黏膜相关淋巴组织型原发性甲状腺边缘区 B 细胞淋巴瘤：罕见疾病的临床表现和转归——改善淋巴瘤生存研究联盟。
Acta Haematol. 2012;127(2):100-4. doi: 10.1159/000333113. Epub 2011 Dec 15.
8
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.配对分析比较利妥昔单抗联合化疗治疗原发性乳腺和淋巴结弥漫性大 B 细胞淋巴瘤患者的结局。
Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30.
9
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.乳腺弥漫性大 B 细胞淋巴瘤患者的临床结局和预后因素；改善淋巴瘤生存（CISL）研究联盟。
BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321.